Onkologie. 2022:16(4):200-205 | DOI: 10.36290/xon.2022.038

News in treatment of gastrointestinal cancer

Kateřina Šašková
Onkologická klinika, FN Motol, Praha

Following article summarizes selected, important, recently evaluated studies that will influence guidelines for treatment of gastrointestinal tumours - oesophageal cancer, gastroesophageal junction tumours, colorectal carcinoma, hepatobiliary cancer and gastrointestinal stromal tumours. In particular, Phase III studies related to the clinical part of oncology were selected.

Keywords: durvalumab, ivosidenib, liposomal irinotecan, nivolumab, pembrolizumab, ripretinib.

Accepted: August 22, 2022; Published: August 24, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šašková K. News in treatment of gastrointestinal cancer. Onkologie. 2022;16(4):200-205. doi: 10.36290/xon.2022.038.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. World Health Organization. WHO [Internet]. 2022 [cit. 2022-04-25]. Available from: https://www.who.int/observatories/global-observatory-on-health-research-and-development/monitoring/number-of-trial-registrations-by-year-location-disease-and-phase-of-development. Go to PubMed...
    2. Ústav zdravotnických informací a statistiky České republiky. Novotvary 2018. [2021]. Available from: https://www.uzis.cz/res/f/008352/novotvary2018.pdf.
    3. Kelly RJ, Ajani JA, Kuzdal J, et al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. New England Journal of Medicine. [Internet]. 2021;384(13):1191-1203 [cit. 2022-04-18]. Available from: doi: 10.1056/NEJMoa2032125. Go to original source... Go to PubMed...
    4. Doki Y, Ajani JA, Kato K, et al. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. New England Journal of Medicine. [Internet]. 2022;386(5):449-462 [cit. 2022-04-18]. Available from: doi: 10.1056/NEJMoa2111380. Go to original source... Go to PubMed...
    5. Janjigian YY, Ajani JA, Moehler M, et al. LBA7 Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study. Annals of Oncology. [Internet]. 2021;32:1329-S1330 [cit. 2022-04-20]. Available from: doi: 10.1016/j.annonc.2021.08.2131. Go to original source...
    6. Státní ústav pro kontrolu léčiv. SÚKL [Internet]. 2022 [cit. 2022-04-30]. Available from: www.sukl.cz.
    7. Okada M, Kato K, Cho BCh, et al. Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3). Clinical Cancer Research. [Internet]. 2022;OF1-OF10 [cit. 2022-04-20]. Available from: doi: 10.1158/1078-0432.CCR-21-0985. Go to original source... Go to PubMed...
    8. Conroy T, Bosset JF, Etienne PL, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. The Lancet Oncology. [Internet]. 2021;22(5):702-715 [cit. 2022-04-24]. Available from: doi: 10.1016/S1470-2045(21)00079-6. Go to original source... Go to PubMed...
    9. Diaz LA, Shiu KK, Kim TW, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. The Lancet Oncology. [Internet]. 2022 [cit. 2022-04-20]. Available from: doi: 10.1016/S1470-2045(22)00197-8. Go to original source... Go to PubMed...
    10. Abou-Alfa GK, Chan SL, Kudo M, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. Journal of Clinical Oncology. [Internet]. 2022;40(4_suppl):379-379 [cit. 2022-04-25]. Available from: doi: 10.1200/JCO.2022.40.4_suppl.379. Go to original source...
    11. Valderrama A, Singhal M, Wang L, Nepal B, Kamble S, Grabner M, Malhotra U, Javle MM. Treatment patterns and clinical outcomes among patients with biliary tract cancers in a large commercially insured US population. Journal of Clinical Oncology. [Internet]. 2022;40(4_suppl):398-398 [cit. 2022-04-28]. Available from: doi: 10.1200/JCO.2022.40.4_suppl.398. Go to original source...
    12. Oh DY, HE AR, Qin S, et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. Journal of Clinical Oncology. [Internet]. 2022;40(4_suppl):378-378 [cit. 2022-06-11]. Available from: doi: 10.1200/JCO.2022.40.4_suppl.378. Go to original source...
    13. Yoo Ch, Kim K, Jeong JH, et al. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. The Lancet Oncology. [Internet]. 2021;22(11):1560-1572 [cit. 2022-04-21]. Available from:10.1016/S1470-2045(21)00486-1. Go to original source... Go to PubMed...
    14. Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. The Lancet Oncology [Internet]. 2020;21(6):796-807 [cit. 2022-04-23]. Available from: doi: 10.1016/S1470-2045(20)30157-1. Go to original source... Go to PubMed...
    15. Zhu AX, Macarulla T, Javle MM, et al. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation. JAMA Oncology. [Internet]. 2021;7(11) [cit. 2022-04-23]. Available from: doi: 10.1001/jamaoncol.2021.3836. Go to original source... Go to PubMed...
    16. Modrá kniha České onkologické společnosti: platnost od 2022 Brno: Masarykův onkologický ústav; 2022.
    17. Symcax M, Somaiah N. Ripretinib for advanced gastrointestinal stromal tumor: Plain language summary of the INVICTUS study. Future Oncology. [Internet]. 2021;17(36): 5007-5012 [cit. 2022-04-23]. Available from: doi: 10.2217/fon-2021-0803. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.